AU2011305786B2 - Biomarkers of renal injury - Google Patents

Biomarkers of renal injury Download PDF

Info

Publication number
AU2011305786B2
AU2011305786B2 AU2011305786A AU2011305786A AU2011305786B2 AU 2011305786 B2 AU2011305786 B2 AU 2011305786B2 AU 2011305786 A AU2011305786 A AU 2011305786A AU 2011305786 A AU2011305786 A AU 2011305786A AU 2011305786 B2 AU2011305786 B2 AU 2011305786B2
Authority
AU
Australia
Prior art keywords
renal
value
injury
kidney
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011305786A
Other languages
English (en)
Other versions
AU2011305786A1 (en
Inventor
John A. Kellum
Kai Singbartl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of AU2011305786A1 publication Critical patent/AU2011305786A1/en
Application granted granted Critical
Publication of AU2011305786B2 publication Critical patent/AU2011305786B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2011305786A 2010-09-24 2011-09-19 Biomarkers of renal injury Active AU2011305786B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38623010P 2010-09-24 2010-09-24
US61/386,230 2010-09-24
US13/235,005 US10557856B2 (en) 2010-09-24 2011-09-16 Biomarkers of renal injury
US13/235,005 2011-09-16
PCT/US2011/052082 WO2012040073A2 (en) 2010-09-24 2011-09-19 Biomarkers of renal injury

Publications (2)

Publication Number Publication Date
AU2011305786A1 AU2011305786A1 (en) 2013-04-11
AU2011305786B2 true AU2011305786B2 (en) 2015-04-23

Family

ID=45871234

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011305786A Active AU2011305786B2 (en) 2010-09-24 2011-09-19 Biomarkers of renal injury

Country Status (12)

Country Link
US (3) US10557856B2 (https=)
EP (1) EP2619577B1 (https=)
JP (1) JP5998143B2 (https=)
KR (1) KR101981745B1 (https=)
CN (1) CN103189745B (https=)
AU (1) AU2011305786B2 (https=)
BR (1) BR112013006935B1 (https=)
CA (1) CA2811658C (https=)
EA (1) EA030622B1 (https=)
MX (1) MX365029B (https=)
NZ (1) NZ608384A (https=)
WO (1) WO2012040073A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
EP3318255B1 (en) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130282390A1 (en) * 2012-04-20 2013-10-24 International Business Machines Corporation Combining knowledge and data driven insights for identifying risk factors in healthcare
WO2013184868A1 (en) * 2012-06-06 2013-12-12 The Cleveland Clinic Foundation Prediction of acute kidney injury from a post-surgical metabolic blood panel
JP6475624B2 (ja) * 2012-10-08 2019-02-27 レリプサ， インコーポレイテッド 高血圧症及び高カリウム血症を治療するためのカリウム結合剤
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
CA2907120C (en) 2013-03-15 2023-10-17 Sera Prognostics, Inc. Biomarkers and methods for predicting preterm birth
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
WO2014210031A1 (en) 2013-06-25 2014-12-31 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Proteomic biomarkers of sepsis in elderly patients
GB201317621D0 (en) * 2013-10-04 2013-11-20 Randox Teoranta Kidney disease biomarker
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US20180038873A1 (en) * 2015-02-05 2018-02-08 University Of Florida Research Foundation, Inc. Use of nhe3 as a biomarker for radiation biodosimetry
EP3196791A1 (de) * 2017-05-02 2017-07-26 Siemens Healthcare GmbH Verfahren zur unterstützung von medizinischem personal, unterstützungssystem, computerprogramm und datenträger
US11771113B2 (en) 2017-05-31 2023-10-03 Mars, Incorporated Methods of diagnosing and treating chronic kidney disease
US11026625B2 (en) * 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
WO2019144081A1 (en) 2018-01-19 2019-07-25 Mars, Incorporated Biomarkers and classification algorithms for chronic kidney disease in cats
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US20190317090A1 (en) * 2018-04-12 2019-10-17 Children's Hospital Medical Center Compositions and methods for forecasting response to lupus nephritis (ln)therapy
US10978176B2 (en) * 2018-06-29 2021-04-13 pulseData Inc. Machine learning systems and methods for predicting risk of renal function decline
EP3821254A1 (en) 2018-07-14 2021-05-19 Mars Incorporated Biomarkers and test models for chronic kidney disease
LT3750536T (lt) 2018-09-24 2026-03-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai
CN109754878B (zh) * 2018-11-30 2023-06-20 平安科技（深圳）有限公司 慢性肾病筛查方法、装置、设备及存储介质
CN109738931B (zh) * 2018-12-18 2022-06-17 上海瑞派益尔科技有限公司 一种肾小球滤过率检测设备
US11350887B2 (en) 2019-08-07 2022-06-07 Fresenius Medical Care Holdings, Inc. Systems and methods for detection of potential health issues
CN110596370B (zh) * 2019-09-17 2023-03-24 广州医科大学附属第五医院 一种检测细菌尿路感染的酶联免疫吸附试剂盒及其应用
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
CN110904219B (zh) * 2019-12-24 2023-04-18 广州市妇女儿童医疗中心 Myh9及ctla4基因多态性位点在指导肾病综合征患儿使用他克莫司中的应用
CN110923310B (zh) * 2019-12-24 2023-04-18 广州市妇女儿童医疗中心 用于指导肾病综合征cyp3a5表达型患儿使用他克莫司的多态性位点
JP7758266B2 (ja) 2020-06-01 2025-10-22 マース インコーポレーテッド イヌの慢性腎臓病のためのシステム及び方法
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
RU2761738C1 (ru) * 2021-06-07 2021-12-13 Алина Владимировна Еремеева Способ отбора детей с дебютом острого пиелонефрита для проведения курса противорецидивной терапии пиелонефрита
WO2022261513A1 (en) * 2021-06-10 2022-12-15 Kang Zhang Methods and systems of detecting and predicting chronic kidney disease and type 2 diabetes using deep learning models
EP4573371A2 (en) * 2022-08-19 2025-06-25 The Johns Hopkins University Diagnosis and treatment of acute kidney injury
US20250001158A1 (en) * 2023-06-28 2025-01-02 Abiomed, Inc. Cardiorenal syndrome (crs) therapy systems and methods
CN117373584B (zh) * 2023-12-08 2024-03-12 北京大学第一医院 一种急性肾损伤的动态预测方法及系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081148A1 (en) * 2008-09-26 2010-04-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Urinary Biomarkers To Predict Long-Term Dialysis

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
JP3290988B2 (ja) 1991-04-11 2002-06-10 バイオサイト・ダイアグノスティックス・インコーポレイテッド 多重リガンドを同時検出する新規接合体及び検定法
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6350571B1 (en) 1996-02-01 2002-02-26 Vinata B. Lokeshwar Methods for detection and evaluation of bladder cancer
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
CN101393165A (zh) * 2007-09-20 2009-03-25 复旦大学附属华山医院 一种检测糖尿病肾病血清标本中差异表达的蛋白质谱的方法
KR20100122495A (ko) * 2008-02-29 2010-11-22 고쿠리츠 다이가쿠 호우징 나고야 다이가쿠 급성 신장 장해 및 예후 추정용 바이오마커 및 그 용도
US20090239242A1 (en) 2008-03-18 2009-09-24 Biotrin Intellectual Properties Limited Method for the early identification and prediction of kidney injury
JP2012501456A (ja) * 2008-08-28 2012-01-19 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
EP2324354B1 (en) * 2008-08-29 2014-07-16 Astute Medical, Inc. Methods for prognosis of acute renal failure
CA2740923A1 (en) 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2009316387B2 (en) * 2008-11-22 2015-01-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20120315649A1 (en) * 2009-08-28 2012-12-13 Astute Medical ,Inc. a corporation Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011075744A1 (en) * 2009-12-20 2011-06-23 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081148A1 (en) * 2008-09-26 2010-04-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Urinary Biomarkers To Predict Long-Term Dialysis

Also Published As

Publication number Publication date
WO2012040073A3 (en) 2012-06-14
CA2811658C (en) 2021-03-30
WO2012040073A2 (en) 2012-03-29
BR112013006935B1 (pt) 2021-02-23
JP5998143B2 (ja) 2016-09-28
EA201390439A1 (ru) 2013-09-30
KR101981745B1 (ko) 2019-05-27
US20240118289A1 (en) 2024-04-11
AU2011305786A1 (en) 2013-04-11
CN103189745B (zh) 2018-05-01
MX2013003321A (es) 2013-10-25
US20120077690A1 (en) 2012-03-29
EP2619577B1 (en) 2017-08-16
US11693014B2 (en) 2023-07-04
EP2619577A4 (en) 2014-04-30
CA2811658A1 (en) 2012-03-29
KR20140001863A (ko) 2014-01-07
US12601746B2 (en) 2026-04-14
EP2619577A2 (en) 2013-07-31
MX365029B (es) 2019-05-21
US10557856B2 (en) 2020-02-11
JP2013539030A (ja) 2013-10-17
CN103189745A (zh) 2013-07-03
NZ608384A (en) 2014-12-24
BR112013006935A2 (pt) 2017-05-30
US20200150132A1 (en) 2020-05-14
EA030622B1 (ru) 2018-09-28

Similar Documents

Publication Publication Date Title
US12601746B2 (en) Biomarkers of renal injury
AU2011213684B2 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2020201732A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010314999B2 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20190227056A1 (en) Methods and compositions for the evaluation of renal injury using hyaluronic acid
AU2011305197B2 (en) Methods and compositions for the evaluation of renal injury using hyaluronic acid
US20120231472A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
HK1186246A (en) Biomarkers of renal injury
HK1186246B (en) Biomarkers of renal injury
AU2015200547A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)